| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJMRA020021 |
| P698 | PubMed publication ID | 12571261 |
| P50 | author | Richard Weinshilboum | Q52447985 |
| P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 529-537 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Inheritance and drug response | |
| P478 | volume | 348 |
| Q37628680 | (13)C breath tests in personalized medicine: fiction or reality? |
| Q92377012 | A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain |
| Q46635550 | A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study |
| Q26827814 | A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics |
| Q35737324 | A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression |
| Q42590601 | A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? |
| Q100517648 | A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? |
| Q36666911 | ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy |
| Q38209972 | ADHD pharmacogenetics across the life cycle: New findings and perspectives. |
| Q82277014 | Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis |
| Q36402208 | Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. |
| Q34249718 | Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey |
| Q36429723 | Advances in the treatment for haematological malignancies |
| Q38183664 | African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. |
| Q43478633 | Analysis of CYP2D6 genotype and response to tetrabenazine |
| Q35828717 | Ancestry and pharmacogenetics of antileukemic drug toxicity |
| Q36814319 | Ancillary risk information and pharmacogenetic tests: social and policy implications |
| Q35608800 | Antiarrhythmic drugs: past, present and future |
| Q35570981 | Antihypertensive therapy: special focus on drug interactions |
| Q46445488 | Applicability of pharmacogenetic studies in daily clinical practice |
| Q37326539 | Applications of genetically modified tools to safety assessment in drug development |
| Q28195157 | Aspirin resistance |
| Q40169397 | Assessing the clinical utility of biomarkers in medicine |
| Q35030197 | Assessment of the pharmacogenomics educational needs of pharmacists. |
| Q35006860 | Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen |
| Q53724655 | Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. |
| Q37150901 | Asthma genetics: personalizing medicine |
| Q35998622 | Asthma treatment in the 21st century: what's next? |
| Q80860599 | Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs |
| Q42939949 | Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events |
| Q44985731 | Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese |
| Q35831792 | CYP2C19 polymorphism and proton pump inhibitors |
| Q42005025 | CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q34794075 | CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. |
| Q37738765 | CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance |
| Q38276429 | Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? |
| Q27488354 | Causality assessment in hepatotoxicity by drugs and dietary supplements |
| Q35621396 | Challenges of implementing pharmacogenetics in the critical care environment |
| Q81703905 | Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems |
| Q64121167 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update |
| Q24632749 | Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing |
| Q36248267 | Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism |
| Q57994495 | Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin |
| Q40500349 | Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory |
| Q91687653 | Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry |
| Q36248030 | Consequences of POR mutations and polymorphisms. |
| Q34975631 | Copy number variants in pharmacogenetic genes |
| Q37362549 | Current developments in genomics and personalized health care: impact on public health |
| Q37513508 | Cytochrome P450 2D6. |
| Q82577163 | Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients |
| Q38099372 | Cytochrome P450 pharmacogenetics in African populations. |
| Q37954366 | Cytochrome P450 polymorphisms and drug-induced interstitial lung disease |
| Q81619713 | Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study |
| Q44899940 | D919G polymorphism of methionine synthase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients |
| Q35959328 | Databases in the area of pharmacogenetics |
| Q73880646 | Decision making in pharmacogenomic diagnosis: is there anything new under the sun? |
| Q58562824 | Defining and Searching Pharmacogenetics and Pharmacogenomics to Identify Its Core Research Journals |
| Q36341743 | Defining the opportunity for pharmacogenetic intervention in primary care |
| Q45421313 | Delivering a pharmacogenetic service: is there a role for genetic counselors? |
| Q37706159 | Delivering systems pharmacogenomics towards precision medicine through mathematics |
| Q25257767 | Developing academic-practice partnerships to enhance the integration of genomics into public health |
| Q35876954 | Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms |
| Q36561076 | Diuretics in pediatrics : current knowledge and future prospects |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q34641494 | Drug induced interstitial lung disease. |
| Q41904703 | Drug interaction and pharmacist |
| Q38025685 | Drug interaction potential of resveratrol. |
| Q36516421 | Drug interactions in cancer therapy |
| Q35881300 | Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid |
| Q47205411 | Drug knowledge bases and their applications in biomedical informatics research. |
| Q37154348 | Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval |
| Q39983997 | Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation |
| Q48230143 | Effect of breviscapine on CYP3A metabolic activity in healthy volunteers |
| Q36350528 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance |
| Q54576089 | Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. |
| Q42678199 | Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study |
| Q36278319 | Emerging concepts in nutrigenomics: a preview of what is to come |
| Q33650172 | Engineering complex tissues |
| Q46730786 | Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. |
| Q36684887 | Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype |
| Q36986803 | Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping |
| Q33261407 | Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay) |
| Q37211743 | Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages |
| Q28762889 | Evolution and medicine: the long reach of "Dr. Darwin" |
| Q35236866 | Expression profiling of drug response--from genes to pathways. |
| Q37784261 | Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate? |
| Q37608475 | Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. |
| Q73917458 | From PGx to molecular diagnostics and personalized medicine |
| Q83509385 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q37806982 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q43115871 | Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription |
| Q55266735 | Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. |
| Q36943648 | Future perspectives for the treatment of pulmonary arterial hypertension |
| Q37963892 | Gene-drug interaction in stroke |
| Q36205840 | Genetic diversity and new therapeutic concepts |
| Q36925216 | Genetic evidence linking lung cancer and COPD: a new perspective |
| Q37822185 | Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics |
| Q36301589 | Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications |
| Q34306333 | Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China |
| Q35922156 | Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity |
| Q39069812 | Genetic screening in arterial hypertension |
| Q42699453 | Genetic testing: hope or hype? |
| Q36207969 | Genetic variability and clinical efficacy of morphine |
| Q30341330 | Genetic variability in CYP3A5 and its possible consequences. |
| Q35812542 | Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm |
| Q97652864 | Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China |
| Q22122050 | Genetic variation, classification and 'race' |
| Q35889610 | Genetically modified mouse models for pharmacogenomic research |
| Q37448915 | Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications |
| Q24654656 | Genetics of migraine and pharmacogenomics: some considerations |
| Q26851506 | Genetics of resistant hypertension: a novel pharmacogenomics phenotype |
| Q37206266 | Genetics of stroke: a review of recent advances. |
| Q36361946 | Genomic influences on schizophrenia-related neurotransmitter systems |
| Q42110131 | Genomic medicine: a new frontier of medicine in the twenty first century |
| Q35038039 | Genomic medicine: genetic variation and its impact on the future of health care |
| Q35252277 | Genomics and drug response |
| Q46563320 | Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing |
| Q45251847 | Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. |
| Q36629931 | Heart valve tissue engineering: concepts, approaches, progress, and challenges |
| Q36986515 | Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics |
| Q36130633 | High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? |
| Q37803415 | How genetic variation affects patient response and outcome to therapy for psoriasis |
| Q30485725 | How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. |
| Q35566353 | Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms |
| Q36830072 | Human nutrition and genetic variation |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q33858887 | Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation |
| Q43148435 | Identification of NTBC metabolites in urine from patients with hereditary tyrosinemia type 1 using two different mass spectrometric platforms: triple stage quadrupole and LTQ-Orbitrap |
| Q48148747 | Imaging genetics: implications for research on variable antidepressant drug response |
| Q36075296 | Immune restoration following hematopoietic stem cell transplantation: an evolving target |
| Q42750010 | Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer |
| Q40955139 | Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. |
| Q36278015 | Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? |
| Q37540497 | In silico vascular modeling for personalized nanoparticle delivery |
| Q46765974 | In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease |
| Q47253422 | Incorporating population-level genetic variability within laboratory models in toxicology: From the individual to the population |
| Q37314893 | Increasing The Genetic Admixture of Available Lines of Human Pluripotent Stem Cells |
| Q28743099 | Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD |
| Q37076331 | Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing |
| Q36831058 | Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations |
| Q35839549 | Inherent and benzo[a]pyrene-induced differential aryl hydrocarbon receptor signaling greatly affects life span, atherosclerosis, cardiac gene expression, and body and heart growth in mice |
| Q38870275 | Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality |
| Q33771344 | Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. |
| Q34686477 | Integrating pharmacokinetics knowledge into a drug ontology: as an extension to support pharmacogenomics. |
| Q37512208 | Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy |
| Q50507170 | Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder. |
| Q54398919 | Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. |
| Q37964574 | Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes |
| Q44820568 | Investigation of serotonin-related genes in antidepressant response |
| Q34173342 | Is the use of sentient animals in basic research justifiable? |
| Q36828947 | Lessons learned from DNA repair defective syndromes |
| Q45179972 | Linking pharmacovigilance with pharmacogenetics |
| Q34054003 | Localizing putative markers in genetic association studies by incorporating linkage disequilibrium into bayesian hierarchical models |
| Q35736945 | Mechanisms in pulmonary toxicology |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q38663993 | Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). |
| Q26052843 | Melatonin treatment of pediatric residents for adaptation to night shift work |
| Q36659167 | Membrane transporter proteins: a challenge for CNS drug development. |
| Q35718630 | Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes |
| Q36811537 | Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology |
| Q37757136 | Methodological and statistical issues in pharmacogenomics |
| Q51711836 | Modeling the genetic etiology of pharmacokinetic-pharmacodynamic links with the ARMA process. |
| Q36252201 | Molecular diagnosis of ATP-binding cassette transporter-related diseases |
| Q35784527 | Moving towards individualized medicine with pharmacogenomics |
| Q58745474 | NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation |
| Q38426328 | Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes |
| Q38198929 | Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis |
| Q64944023 | Omics based approach for biodiscovery of microbial natural products in antibiotic resistance era. |
| Q38041608 | Ontogeny and drug metabolism in newborns |
| Q35946283 | Ontology-based knowledge management of troglitazone-induced hepatotoxicity |
| Q90734352 | Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors |
| Q36433595 | Overview of the pharmacogenetics of asthma treatment. |
| Q36762377 | PGMD: a comprehensive manually curated pharmacogenomic database |
| Q37247869 | Pathways to the best fit of triptans for migraine patients. |
| Q89102964 | Patient HLA Germline Variation and Transplant Survivorship |
| Q37867275 | Patient factors that influence warfarin dose response |
| Q28082746 | Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine |
| Q36559160 | Personalized genomic medicine: a future prerequisite for the prevention of coronary artery disease. |
| Q36193093 | Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective |
| Q36306729 | Personalized medicine in cardiovascular diseases |
| Q43144906 | Personalizing health care--is this the right time for warfarin? |
| Q35772582 | Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia |
| Q34557833 | Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure |
| Q52322328 | Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations. |
| Q42965039 | Pharmacogenetics |
| Q35889619 | Pharmacogenetics - five decades of therapeutic lessons from genetic diversity |
| Q60620182 | Pharmacogenetics and Pharmacovigilance |
| Q35097430 | Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? |
| Q35173693 | Pharmacogenetics and clinical gastroenterology |
| Q36404764 | Pharmacogenetics and diseases of the colon |
| Q37786726 | Pharmacogenetics and forensic toxicology |
| Q56773941 | Pharmacogenetics and geographical ancestry: implications for drug development and global health |
| Q36909252 | Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. |
| Q37618221 | Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. |
| Q40165805 | Pharmacogenetics at 50: genomic personalization comes of age. |
| Q37150913 | Pharmacogenetics in acute lymphoblastic leukemia |
| Q38115822 | Pharmacogenetics in dermatology: a patient-centered update. |
| Q35692680 | Pharmacogenetics in the treatment of breast cancer |
| Q37791155 | Pharmacogenetics of Osteoporosis-Related Bone Fractures: Moving Towards the Harmonization and Validation of Polymorphism Diagnostic Tools |
| Q37430401 | Pharmacogenetics of cardiovascular drug therapy |
| Q24676890 | Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy |
| Q41973110 | Pharmacogenetics of outcome in children with acute lymphoblastic leukemia |
| Q47309064 | Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. |
| Q24537990 | Pharmacogenetics, pharmacogenomics and ecogenetics |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q45220579 | Pharmacogenetics: Important aspects for dermatology |
| Q34273202 | Pharmacogenetics: potential for individualized drug therapy through genetics |
| Q38678653 | Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients |
| Q36438205 | Pharmacogenomics and antidepressant drugs |
| Q38983589 | Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. |
| Q36836583 | Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease |
| Q36273420 | Pharmacogenomics and therapeutic prospects in Alzheimer's disease |
| Q37592250 | Pharmacogenomics and therapeutic strategies for dementia |
| Q36255125 | Pharmacogenomics in depression and antidepressants |
| Q50540783 | Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine |
| Q35120829 | Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. |
| Q46856156 | Pharmacogenomics of tamoxifen and aromatase inhibitors |
| Q37367170 | Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery |
| Q56446183 | Pharmacogenomics steps toward personalized medicine |
| Q37646842 | Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. |
| Q35876017 | Pharmacogenomics: bench to bedside |
| Q33375573 | Pharmacogenomics: candidate gene identification, functional validation and mechanisms |
| Q36522947 | Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase |
| Q36658763 | Pharmacogenomics: challenges and opportunities |
| Q35116109 | Pharmacogenomics: implications and considerations for pharmacists |
| Q35695688 | Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections |
| Q38479485 | Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study |
| Q35622678 | Pharmacologic issues in the critically ill. |
| Q36505060 | Pharmacological perspectives on the detoxification of plant secondary metabolites: implications for ingestive behavior of herbivores. |
| Q52651144 | Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. |
| Q41265929 | Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria |
| Q35741743 | Physiology, genetics, and cardiovascular disease: focus on African Americans |
| Q38332193 | PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis |
| Q30839905 | Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. |
| Q34221423 | Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder |
| Q30572528 | Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol |
| Q90298821 | Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort |
| Q41679231 | Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients |
| Q36180606 | Priorities and standards in pharmacogenetic research |
| Q37082500 | Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues |
| Q35237152 | Psychiatric pharmacogenomic testing in clinical practice |
| Q45391322 | Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. |
| Q37807282 | Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects |
| Q61959358 | Role of Cytochrome P450 Polymorphisms in the Development of Pulmonary Drug Toxicity |
| Q48029721 | SULT1A1 copy number variation: ethnic distribution analysis in an Indian population |
| Q58663678 | Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? |
| Q37948029 | Sedation and analgesia in the mechanically ventilated patient |
| Q34567238 | Sequencing complex diseases With HapMap |
| Q46396210 | Sequencing drug response with HapMap |
| Q37229060 | Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder |
| Q38243174 | Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective. |
| Q40285992 | Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors |
| Q36192738 | Statin response and pharmacokinetics variants |
| Q34599933 | Stochastic modeling of systems mapping in pharmacogenomics. |
| Q37635110 | Stroke pharmacogenomics |
| Q46058560 | Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients |
| Q24607331 | Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase |
| Q34060437 | Sulfotransferase gene copy number variation: pharmacogenetics and function |
| Q90575870 | Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases |
| Q24629614 | Systematic reviews of animal models: methodology versus epistemology |
| Q36212769 | Systems-ADME/Tox: resources and network approaches |
| Q35543090 | Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues |
| Q35876022 | Technology platforms for pharmacogenomic diagnostic assays |
| Q36475111 | The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects |
| Q92811652 | The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology |
| Q35207554 | The application of functional genomics to Alzheimer's disease |
| Q80058663 | The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants |
| Q36773493 | The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy |
| Q35994975 | The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis |
| Q36748157 | The effect of HapMap on cardiovascular research and clinical practice |
| Q46758734 | The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics |
| Q36749461 | The evolving role of drug metabolism in drug discovery and development |
| Q40167765 | The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals |
| Q36605965 | The genetics of health |
| Q80149489 | The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population |
| Q35081312 | The institutional review board is an impediment to human research: the result is more animal-based research |
| Q35859128 | The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies |
| Q92942918 | The need for rapid therapeutic efficacy testing for cancer therapy |
| Q35817019 | The role of cost-effectiveness analysis in the era of pharmacogenomics |
| Q38163945 | The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. |
| Q35814374 | The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease |
| Q34575544 | Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity |
| Q36582619 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance |
| Q50593742 | Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. |
| Q33372321 | Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation |
| Q33625656 | Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme |
| Q36426772 | Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions |
| Q30428413 | Tolerance and withdrawal from prolonged opioid use in critically ill children |
| Q36379398 | Transcreener: screening enzymes involved in covalent regulation |
| Q81244699 | Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation |
| Q36653352 | Using EEG to monitor anesthesia drug effects during surgery |
| Q36223433 | Using PharmGKB to train text mining approaches for identifying potential gene targets for pharmacogenomic studies |
| Q37733572 | Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? |
| Q84176010 | Using patient DNA to optimize therapy in heart failure patients: a move toward perfection |
| Q42717833 | Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
| Q35543817 | Web resources for pharmacogenomics |
| Q35164680 | What is next in pharmacogenomics? Translating it to clinical practice |
| Q36720898 | Why personalized medicine will fail if we stay the course |
| Q79381460 | [Genetic variability in susceptibility to and severity of pneumonia] |
| Q79437519 | [Pharmacogenetics I. Concept, history, objectives and areas of study] |
| Q54324052 | [Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer]. |
Search more.